Does ArteraAI predict the benefit from adding abiraterone to ADT in patients with nonmetastatic high risk prostate cancer per the STAMPEDE trial criteria?
Does prophylactic sucralfate reduce the risk of grade 2+ esophagitis during thoracic RT?
In ONE-SHOT, what was the prescription dose for single fraction SBRT for prostate cancer?
What was the rate of bladder intact EFS in the INDIBLADE trial of induction immunotherapy and chemoradiation for bladder preservation?
Answers
Yes. Those with a very high risk score saw improved MFS with abiraterone whereas those with a standard high risk score did not.
No. In this randomized trial, there was no reduction in opioid use or esophagitis with prophylactic use.
19 Gy. The primary endpoint of biochemical recurrence free survival was 92.9% at 3 years and 88% at 5 years. There were no acute grade 3 GU events, 42.5% had grade 1 GU events, and 20% had grade 2 GU events.
78% with a striking overall survival of 96%. The vast majority (90%) proceeded to chemoradiation while only 12% ultimately required cystectomy. | QuadShot News
Does prophylactic sucralfate reduce the risk of grade 2+ esophagitis during thoracic RT?
In ONE-SHOT, what was the prescription dose for single fraction SBRT for prostate cancer?
What was the rate of bladder intact EFS in the INDIBLADE trial of induction immunotherapy and chemoradiation for bladder preservation?
Answers
Yes. Those with a very high risk score saw improved MFS with abiraterone whereas those with a standard high risk score did not.
No. In this randomized trial, there was no reduction in opioid use or esophagitis with prophylactic use.
19 Gy. The primary endpoint of biochemical recurrence free survival was 92.9% at 3 years and 88% at 5 years. There were no acute grade 3 GU events, 42.5% had grade 1 GU events, and 20% had grade 2 GU events.
78% with a striking overall survival of 96%. The vast majority (90%) proceeded to chemoradiation while only 12% ultimately required cystectomy. | QuadShot News